MBX Biosciences Common Stock Statistics
Share Statistics
MBX Biosciences Common Stock has 33.42M
shares outstanding. The number of shares has increased by null%
in one year.
| Shares Outstanding | 33.42M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 61,623 |
| FTD / Avg. Volume | 21.61% |
Short Selling Information
The latest short interest is 5.38M, so 16.1% of the outstanding
shares have been sold short.
| Short Interest | 5.38M |
| Short % of Shares Out | 16.1% |
| Short % of Float | 32.38% |
| Short Ratio (days to cover) | 18.15 |
Valuation Ratios
The PE ratio is -9.94 and the forward
PE ratio is -4.55.
MBX Biosciences Common Stock's PEG ratio is
0.1.
| PE Ratio | -9.94 |
| Forward PE | -4.55 |
| PS Ratio | 0 |
| Forward PS | 9.5 |
| PB Ratio | 2.39 |
| P/FCF Ratio | -11.08 |
| PEG Ratio | 0.1 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for MBX Biosciences Common Stock.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 24.19,
with a Debt / Equity ratio of 0.
| Current Ratio | 24.19 |
| Quick Ratio | 24.19 |
| Debt / Equity | 0 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,440,046.51 |
| Employee Count | 43 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by null% in the
last 52 weeks. The beta is -0.89, so MBX Biosciences Common Stock's
price volatility has been lower than the market average.
| Beta | -0.89 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 8.98 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 67.69 |
| Average Volume (20 Days) | 285,164 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -68.19M |
| Net Income | -61.92M |
| EBITDA | -67.95M |
| EBIT | -68.19M |
| Earnings Per Share (EPS) | 0 |
Full Income StatementBalance Sheet
The company has 49.35M in cash and 171K in
debt, giving a net cash position of 49.18M.
| Cash & Cash Equivalents | 49.35M |
| Total Debt | 171K |
| Net Cash | 49.18M |
| Retained Earnings | -137.5M |
| Total Assets | 245.93M |
| Working Capital | 233.79M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -54.68M
and capital expenditures -874K, giving a free cash flow of -55.55M.
| Operating Cash Flow | -54.68M |
| Capital Expenditures | -874K |
| Free Cash Flow | -55.55M |
| FCF Per Share | -1.66 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
